新辅助化疗和ISR对直肠癌患者肛肠动力学排便功能的影响

doi:10.3969/j.issn.1006-6233.2020.01.015

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1214 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的:探究新辅助化疗辅助ISR对直肠癌患者术后控便功能及肛肠动力学的影响。方法:回顾性的选取2015年1月至2016年11月我院行ISR术的73例直肠癌患者作为研究对象,依据治疗方式分为两组,对照组(35例)行常规ISR术,观察组(38例)行新辅助化疗联合ISR术。比较两组患者术后肛肠动力学、排便能力及不良反应。结果:两组患者在不同时点组内比较,肛管高压带(HPZ)、肛管静息压(ARP)、肛管最大收缩压(MSP)均变化显著(P<0.05);同时点组间比较,术后1个月、术后3个月及术后6个月,对照组患者ARP、MSP均显著高于对照组患者(P<0.05)。两组患者术后控便能力无显著差异(P>0.05)。两组患者均发生感染、肠梗阻、尿潴留等事件,但两组各不良事件的发生率无显著差异(P>0.05)。结论:新辅助化疗联合ISR治疗直肠癌患者,虽对肛肠动力学产生一定的影响,但并不增加排便困难及其他不良事件。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	刘洋
	李大鹏
	高飞
	王琳

关键词 ：直肠癌, ISR, 新辅助化疗, 肛肠功能

Abstract：Objective: To explore the effects of neoadjuvant chemotherapy and ISR on anorectal dynamics and defecation in patients with rectal cancer. Methods: 73 rectal cancer patients who underwent ISR in our hospital from January 2015 to November 2016 were selected as the study objects. According to the treatment methods, they were divided into two groups: the control group (35 cases) received conventional ISR, and the observation group (38 cases) received neoadjuvant chemotherapy combined with ISR. The anorectal motility, defecation ability and adverse reactions were compared between the two groups. Results: In the two groups, the changes of hpz, ARP and MSP were significant (P < 0.05) compared with each other at different time points, and the changes of ARP and MSP in the control group were significantly higher than those in the control group at 1 month, 3 months and 6 months after operation (P < 0.05). There was no significant difference between the two groups (P > 0.05). Infection, intestinal obstruction, urinary retention and other events occurred in the 2 groups * but there was no significant difference in the incidence of adverse events between the 2 groups (P>0.05). Conclusion: Neoadjuvant chemotherapy combined with ISR in the treatment of rectal cancer has certain influence on anorectal motility, but it does not increase defecation difficulties and other adverse events.

Key words： Rectal cancer ISR Neoadjuvant chemotherapy Anorectal function

基金资助:沈阳市卫生和计划生育委员会科研项目,(编号:2018SY572)

引用本文:

刘洋, 李大鹏, 高飞, 王琳. 新辅助化疗和ISR对直肠癌患者肛肠动力学排便功能的影响[J]. 河北医学, 2020, 26(1): 63-66.
LIU Yang, LI Dapeng, GAO Fei, et al. Effects of Neoadjuvant Chemotherapy and ISR on Anorectal Dynamics and Defecation in Patients with Rectal Cancer. HeBei Med, 2020, 26(1): 63-66.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2020.01.015 或 http://www.hbyxzzs.cn/CN/Y2020/V26/I1/63

[1] Dulskas A, Miliauskas P, Tikuisis R, et al. The functional results of radical rectal cancer surgery: review of the literature[J]. Acta Chirurgica Belgica, 2016, 116(1):1~10.
[2] 赵任, 蒋奕玫.直肠癌外科手术治疗进展[J].外科理论与实践,2016,21(6):13~16.
[3] Shirouzu K, Murakami N, Akagi Y. Intersphincteric resection for very low rectal cancer: a review of the updated literature[J]. Annals of Gastroenterological Surgery, 2017, 1(1):24~32.
[4] 胡聪,杨君,廖坤,等.新辅助化疗对手术根治性结直肠癌组织RSK4蛋白表达及术后淋巴结检出数目的影响[J].结直肠肛门外科,2016,20(2):146~149.
[5] 中华人民共和国卫生和计划生育委员会医政医管局.结直肠癌诊疗规范(2015年版)[J].中华外科杂志,2015,53(11):881~894.
[6] 王锡山.中美结直肠癌流行病学特征对比及防控策略分析[J].中华结直肠疾病电子杂志,2019,8(1):7~11.
[7] 庞吉超,王平怀.MRI与螺旋CT在直肠癌术前分期诊断中的应用价值比较[J].河北医学,2018,24(11):1817~1821.
[8] 李文,于昭,李胜凯,等.ADC值与直肠腺癌分化程度及T分期的相关性研究[J].中国中西医结合影像学杂志,2017,15(4):402~405,409.
[9] Scala D,Niglio A, Pace U, et al. Laparoscopic intersphincteric resection: indications and results[J]. Updates Surg, 2016, 68(1):85~91.
[10] 罗丽丹,陈海冰,许进勇,等.新辅助放化疗对局部进展期直肠癌保肛术后排便功能的影响[J].现代肿瘤医学,2018,26(8):1232~1236.
[11] 黄文伟,童仕伦,郑勇斌.新辅助放化疗对中低位直肠癌患者排便状况的影响[J].实用癌症杂志,2016,26(2):267~269.
[12] Ryan J E, Warrier S K, Lynch A C, et al. Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review[J]. Colorectal Disease, 2016, 18(3):234~246.